FDA Approves ATS Medical’s 3f Aortic Biprosthesis, 3f Enable Still in the Works
The FDA has approved ATS Medical’s 3f Aortic Bioprosthesis (3fAB), a poorly named, but potentially revolutionary pericardial aortic tissue valve. […]
Read more »Clarient: Q3 Revenues up 59%; Raises Guidance
Third quarter revenues at Clarient increased 59% to $19.0 million from the $11.9 million reported in Q3 2007. This marks […]
Read more »[Video Profile] Sherlock-NMD
When an athlete is injured, their career and value to the team are at risk. At all levels of athletics, […]
Read more »Cynosure: Profitable, Growing and Flush with Cash, but Investors Don’t Care
Quarterly revenues at Cynosure, a developer of laser-based aesthetic systems, grew 21% year-over-year, from $31.5 million in Q3 2007 to […]
Read more »Langer Sheds Orthotics Business to Cut the Fat
Only months after Langer sold its Bi-Op subsidiary for less than its purchase price, the company announced the sale of […]
Read more »Nothing But Sunshine and Roses for Endologix, Save its Share Price
Endologix, developer of a treatment for abdominal aortic aneurysms (AAA), saw revenues increase 42% in its third quarter. The company […]
Read more »Candela Explores Strategic Alternatives in Challenging Aesthetics Market
First Quarter Results: Revenues at Candela Corporation, a maker of aesthetic lasers, decreased 24 percent year-over-year, to $26.9 million in […]
Read more »Business as Usual for Endologix as it Considers $98 Million Buyout
More good news from Endologix, the Irvine, CA-based company mulling over a $98 million buyout bid from hedge fund Elliott […]
Read more »NxStage Medical Signs Long-Term Supply Agreement with Renal Advantage
NxStage Medical has signed a long-term product supply agreement with Renal Advantage (RAI), the fourth largest provider of dialysis services […]
Read more »